Download App

Log in to access Online Inquiry
Company Overview More
Cinda Biopharmaceutical is an investment holding company mainly engaged in biopharmaceuticals. The company and its subsidiaries are engaged in the research and development of antibody and protein pharmaceutical products, drug sales and distribution, as well as providing consulting and R & D services. The company's main product is Dabeshu (Xindirizumab injection), which is used to treat relapsed or refractory classical Hodgkin's lymphoma. The company's products also include adamumab bioanalogue IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab bioanalogue IBI-305 is used in the treatment of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer (NSCLC). Rituximab bioanalogue IBI-301 is used in the treatment of non-Hodgkin's lymphoma and chronic lymphoblastic leukemia. The company's products are used in the fields of oncology, metabolism, immunology and fundus diseases.
CEO: Dechao Yu
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > 01801 INNOVENT BIO > Detailed Quotes

01801 INNOVENT BIO

22.750+1.150+5.32%
Closed 05/20 16:08 CCT
High
23.200
Open
22.250
Turnover
195.66M
Low
22.000
Pre Close
21.600
Volume
8.63M
Market Cap
33.36B
P/E(TTM)
Loss
52wk High
95.750
Shares
1.47B
P/E(Static)
Loss
52wk Low
18.060
Float Cap
33.36B
Bid/Ask %
1.96%
Historical High
107.100
Shs Float
1.47B
Volume Ratio
0.81
Historical Low
14.000
Dividend TTM
--
Div Yield TTM
--
P/B
2.64
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.59%
Amplitude
5.56%
Avg Price
22.662
Lot Size
500
Float Cap
33.36B
Bid/Ask %
1.96%
Historical High
107.100
Shs Float
1.47B
Volume Ratio
0.81
Historical Low
14.000
Dividend TTM
--
P/B
2.64
Dividend LFY
--
Turnover Ratio
0.59%
Amplitude
5.56%
Avg Price
22.662
Lot Size
500
Price Forecast

No Data

News

Comment